David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 23.09% |
| 2 | Technology | 17.04% |
| 3 | Healthcare | 13.44% |
| 4 | Consumer Discretionary | 13.38% |
| 5 | Financials | 7.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SFLY
2126
PUT
DELISTED
Shutterfly, Inc.
SFLY
| $1.97M | ﹤0.01% |
48,500
+10,000
| +26% | +$439K |
|
|
HTBK
2127
DELISTED
Heritage Commerce
HTBK
| $1.97M | ﹤0.01% |
162,482
-37,807
| -19% | -$494K |
|
2128
Albany International
AIN
$1.68B
| $1.96M | ﹤0.01% |
27,433
-3,763
| -12% | -$268K |
|
2129
Seres Therapeutics
MCRB
$49.7M
| $1.96M | ﹤0.01% |
14,265
-1,132
| -7% | -$138K |
|
2130
CALL
Lennox International
LII
$13.5B
| $1.96M | ﹤0.01% |
+7,400
| New | +$1.77M |
|
2131
PUT
HCA Healthcare
HCA
$91.5B
| $1.96M | ﹤0.01% |
15,000
| – | – |
|
2132
Ardelyx
ARDX
$986M
| $1.95M | ﹤0.01% |
697,513
+184,536
| +36% | +$480K |
|
|
OPB
2133
DELISTED
Opus Bank Common Stock
OPB
| $1.93M | ﹤0.01% |
97,609
+7,932
| +9% | +$168K |
|
|
CYBR
2134
CALL
DELISTED
CyberArk
CYBR
| $1.93M | ﹤0.01% |
16,200
+8,000
| +98% | +$765K |
|
|
WBC
2135
CALL
DELISTED
WABCO HOLDINGS INC.
WBC
| $1.93M | ﹤0.01% |
+14,600
| New | +$1.8M |
|
2136
CALL
Newell Brands
NWL
$2.56B
| $1.92M | ﹤0.01% |
125,000
-119,100
| -49% | -$2.19M |
|
2137
United Airlines
UAL
$37B
| $1.92M | ﹤0.01% |
24,046
+4,046
| +20% | +$341K |
|
2138
Evolution Petroleum
EPM
$126M
| $1.92M | ﹤0.01% |
283,922
+190,204
| +203% | +$1.38M |
|
2139
PUT
Veeva Systems
VEEV
$46.3B
| $1.92M | ﹤0.01% |
15,100
-20,800
| -58% | -$2.35M |
|
2140
Enpro
NPO
$6.54B
| $1.92M | ﹤0.01% |
29,713
+3,957
| +15% | +$261K |
|
2141
Regional Management Corp
RM
$299M
| $1.91M | ﹤0.01% |
78,317
-1,766
| -2% | -$47K |
|
2142
PUT
MGM Resorts International
MGM
$10.9B
| $1.91M | ﹤0.01% |
74,500
-233,800
| -76% | -$6.41M |
|
2143
Badger Meter
BMI
$4.01B
| $1.91M | ﹤0.01% |
34,326
+10,127
| +42% | +$563K |
|
2144
HealthEquity
HQY
$7.74B
| $1.91M | ﹤0.01% |
+25,799
| New | +$1.81M |
|
2145
Old Republic International
ORI
$10.2B
| $1.91M | ﹤0.01% |
91,187
-82,561
| -48% | -$1.72M |
|
2146
TherapeuticsMD
TXMD
$26M
| $1.9M | ﹤0.01% |
+7,806
| New | +$2.07M |
|
2147
Expro Ltd
XPRO
$1.99B
| $1.9M | ﹤0.01% |
50,898
-43,063
| -46% | -$1.57M |
|
2148
Macerich
MAC
$6.85B
| $1.89M | ﹤0.01% |
43,701
-121,719
| -74% | -$5.38M |
|
2149
Commercial Vehicle Group
CVGI
$127M
| $1.88M | ﹤0.01% |
245,357
+29,210
| +14% | +$219K |
|
2150
PUT
Sea Limited
SE
$71.9B
| $1.88M | ﹤0.01% |
+80,000
| New | +$1.4M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $2.66B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 23% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.